APAC Age-Related Updated Macular Degeneration (AMD) Disease - ANTI VEGF Market

Description

List of Tables

The Asia-Pacific age-related macular degeneration (AMD) disease - anti VEGF market is expected to reach USD 3,160.60 million by 2031 from USD 1,734.70 million in 2023, growing with a CAGR of 7.9% in the forecast period of 2024 to 2031.

Market Segmentation

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales, Direct Tenders, and Others), Country (Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam and rest of Asia-Pacific) - Industry Trends and Forecast to 2031.

Overview of Asia-Pacific Age-Related Macular Degeneration (AMD) Disease - ANTI VEGF Market Dynamics

Driver
Rising prevalence of age-related macular degeneration
Restraint
High-Cost of treatment and procedures
Opportunity
Increase in awareness and treatment seeking rate of AMD

Market Players

Some of the major market players operating in the Asia-Pacific Age-Related Macular Degeneration (AMD) Disease - ANTI VEGF market are listed below:

Regeneron Pharmaceuticals Inc. ()
Novartis AG
Bayer AG
IVERIC bio, Inc., An Astellas Company
Genentech, Inc. (A subsidiary of F. Hoffmann-La Roche Ltd)
Johnson & Johnson Services, Inc.
KODIAK SCIENCES INC.
Adverum Biotechnologies, Inc.
Biogen
Sylentis, S.A.
MeiraGTx Limited
Ionis Pharmaceuticals
Gensight Bilogics
OGUGEN, INC.
Outlook Therapeutics, Inc.
REGENXBIO Inc.

1 INTRODUCTION 15

1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET 15
1.4 LIMITATIONS 17
1.5 MARKETS COVERED 17

2 MARKET SEGMENTATION 19

2.1 MARKETS COVERED 19
2.2 GEOGRAPHICAL SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 25
2.7 TYPE LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32

4 PREMIUM INSIGHTS 34

4.1 PESTEL 35
4.2 PORTERS_ 36
4.3 PRICING ANALYSIS 37
4.4 STRATEGIC INITIATIVES 38

5 REGULATORY FRAMEWORK 39

6 MARKET OVERVIEW 42

6.1 DRIVERS 44
- 6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 44
- 6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 44
- 6.1.3 INCREASE IN PIPELINE PRODUCTS 45
- 6.1.4 INCREASING GERIATRIC POPULATION 46
- 6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 47
6.2 RESTRAINTS 47
- 6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 47
- 6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 48
6.3 OPPORTUNITIES 48
- 6.3.1 INCREASING RESEARCH AND DEVELOPMENT 48
- 6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 49
- 6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 49
6.4 CHALLENGES 49
- 6.4.1 LIMITED ACCESS TO TREATMENT 49
- 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 50

7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE 51

7.1 OVERVIEW 52
7.2 WET AMD 55
- 7.2.1 MEDICATIONS 56
  - 7.2.1.1 ANTI-VEGF THERAPY 56
  - 7.2.1.2 OTHERS 56
- 7.2.2 SURGERY 56
7.3 DRY AMD 57

8 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER 58

8.1 OVERVIEW 59
8.2 HOSPITALS 62
8.3 SPECIALTY CLINICS 63
8.4 AMBULATORY SURGICAL CENTERS 63
8.5 HOME HEALTHCARE 64
8.6 OTHERS 64

9 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL 65

9.1 OVERVIEW 66
9.2 RETAIL SALES 69
- 9.2.1 HOSPITAL PHARMACIES 70
- 9.2.2 RETAIL PHARMACIES 70
- 9.2.3 OTHERS 70
9.3 DIRECT TENDER 71

10 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION 72

10.1 ASIA-PACIFIC 74
- 10.1.1 CHINA 77
- 10.1.2 JAPAN 79
- 10.1.3 INDIA 81
- 10.1.4 SOUTH KOREA 83
- 10.1.5 AUSTRALIA 85
- 10.1.6 SINGAPORE 87
- 10.1.7 THAILAND 89
- 10.1.8 INDONESIA 91
- 10.1.9 PHILIPPINES 93
- 10.1.10 MALAYSIA 95
- 10.1.11 VIETNAM 97
- 10.1.12 REST OF ASIA-PACIFIC 99

11 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 100

11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 100

12 SWOT ANALYSIS 101

13 COMPANY PROFILE 102

13.1 REGENERON PHARMACEUTICALS INC. 102
- 13.1.1 COMPANY SNAPSHOT 102
- 13.1.2 REVENUE ANALYSIS 103
- 13.1.3 COMPANY SHARE ANALYSIS 103
- 13.1.4 PRODUCT PORTFOLIO 104
- 13.1.5 RECENT DEVELOPMENTS 104
13.2 BAYER AG 105
- 13.2.1 COMPANY SNAPSHOT 105
- 13.2.2 REVENUE ANALYSIS 105
- 13.2.3 COMPANY SHARE ANALYSIS 106
- 13.2.4 PRODUCT PORTFOLIO 106
- 13.2.5 RECENT DEVELOPMENT 107
13.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD) 108
- 13.3.1 COMPANY SNAPSHOT 108
- 13.3.2 COMPANY SHARE ANALYSIS 108
- 13.3.3 PRODUCT PORTFOLIO 109
- 13.3.4 RECENT DEVELOPMENT 109
13.4 NOVARTIS AG 110
- 13.4.1 COMPANY SNAPSHOT 110
- 13.4.2 REVENUE ANALYSIS 110
- 13.4.3 COMPANY SHARE ANALYSIS 111
- 13.4.4 PRODUCT PORTFOLIO 111
- 13.4.5 RECENT DEVELOPMENTS 112
  - 13.4.5.1 AGREEMENT 112
13.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.) 113
- 13.5.1 COMPANY SNAPSHOT 113
- 13.5.2 REVENUE ANALYSIS 113
- 13.5.3 COMPANY SHARE ANALYSIS 114
- 13.5.4 PRODUCT PORTFOLIO 114
- 13.5.5 RECENT DEVELOPMENT 115
13.6 ADVERUM BIOTECHNOLOGIES, INC. 116
- 13.6.1 COMPANY SNAPSHOT 116
- 13.6.2 PRODUCT PORTFOLIO 116
- 13.6.3 RECENT DEVELOPMENT 117
13.7 BIOGEN 118
- 13.7.1 COMPANY SNAPSHOT 118
- 13.7.2 PRODUCT PORTFOLIO 118
- 13.7.3 RECENT DEVELOPMENT 118
13.8 GENSIGHT BIOLOGICS 119
- 13.8.1 COMPANY SNAPSHOT 119
- 13.8.2 REVENUE ANALYSIS 119
- 13.8.3 PRODUCT PORTFOLIO 120
- 13.8.4 RECENT DEVELOPMENTS 120
13.9 IONIS PHARMACEUTICALS 121
- 13.9.1 COMPANY SNAPSHOT 121
- 13.9.2 REVENUE ANALYSIS 121
- 13.9.3 PRODUCT PORTFOLIO 122
- 13.9.4 RECENT DEVELOPMENTS 122
13.10 JOHNSON &JOHNSON SERVICES, INC. 123
- 13.10.1 COMPANY SNAPSHOT 123
- 13.10.2 REVENUE ANALYSIS 123
- 13.10.3 PRODUCT PORTFOLIO 124
- 13.10.4 RECENT DEVELOPMENTS 124
13.11 KODIAK SCIENCES INC. 126
- 13.11.1 COMPANY SNAPSHOT 126
- 13.11.2 PRODUCT PORTFOLIO 126
- 13.11.3 RECENT DEVELOPMENTS 126
13.12 MEIRAGTX LIMITED 127
- 13.12.1 COMPANY SNAPSHOT 127
- 13.12.2 PRODUCT PORTFOLIO 127
- 13.12.3 RECENT DEVELOPMENTS 127
13.13 OCUGEN, INC. 129
- 13.13.1 COMPANY SNAPSHOT 129
- 13.13.2 PRODUCT PORTFOLIO 129
- 13.13.3 RECENT DEVELOPMENTS 130
13.14 OUTLOOK THERAPEUTICS, INC. 131
- 13.14.1 COMPANY SNAPSHOT 131
- 13.14.2 PRODUCT PORTFOLIO 131
- 13.14.3 RECENT DEVELOPMENT 131
13.15 REGENXBIO INC. 132
- 13.15.1 COMPANY SNAPSHOT 132
- 13.15.2 PRODUCT PORTFOLIO 132
- 13.15.3 RECENT DEVELOPMENTS 133
13.16 SYLENTIS, S.A. 134
- 13.16.1 COMPANY SNAPSHOT 134
- 13.16.2 PRODUCT PORTFOLIO 134
- 13.16.3 RECENT DEVELOPMENT 134

14 QUESTIONNAIRE 135

15 RELATED REPORTS 138

LIST OF TABLES

TABLE 1 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 55
TABLE 2 ASIA PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 55
TABLE 3 ASIA PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 55
TABLE 4 ASIA PACIFIC MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
TABLE 5 ASIA PACIFIC DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 57
TABLE 6 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 62
TABLE 7 ASIA PACIFIC HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION) 62
TABLE 8 ASIA PACIFIC SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 63
TABLE 9 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 63
TABLE 10 ASIA PACIFIC HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 64
TABLE 11 ASIA PACIFIC OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 64
TABLE 12 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 69
TABLE 13 ASIA PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 69
TABLE 14 ASIA PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 70
TABLE 15 ASIA PACIFIC DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 71
TABLE 16 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 74
TABLE 17 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 75
TABLE 18 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 75
TABLE 19 ASIA-PACIFIC MEDICATION IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 75
TABLE 20 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 75
TABLE 21 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 76
TABLE 22 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 76
TABLE 23 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 77
TABLE 24 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 77
TABLE 25 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 77
TABLE 26 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 78
TABLE 27 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 78
TABLE 28 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 78
TABLE 29 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 79
TABLE 30 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 79
TABLE 31 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 79
TABLE 32 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 80
TABLE 33 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 80
TABLE 34 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 80
TABLE 35 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 81
TABLE 36 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 81
TABLE 37 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 81
TABLE 38 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 82
TABLE 39 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 82
TABLE 40 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 82
TABLE 41 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 83
TABLE 42 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 83
TABLE 43 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 83
TABLE 44 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 84
TABLE 45 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 84
TABLE 46 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 84
TABLE 47 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 85
TABLE 48 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 85
TABLE 49 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 85
TABLE 50 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 86
TABLE 51 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 86
TABLE 52 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 86
TABLE 53 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 87
TABLE 54 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 87
TABLE 55 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 87
TABLE 56 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 88
TABLE 57 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 88
TABLE 58 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 88
TABLE 59 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 89
TABLE 60 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 89
TABLE 61 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 89
TABLE 62 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 90
TABLE 63 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 90
TABLE 64 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 90
TABLE 65 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 91
TABLE 66 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 91
TABLE 67 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 91
TABLE 68 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 92
TABLE 69 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 92
TABLE 70 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 92
TABLE 71 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 93
TABLE 72 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 93
TABLE 73 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 93
TABLE 74 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 94
TABLE 75 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 94
TABLE 76 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 94
TABLE 77 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 95
TABLE 78 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 95
TABLE 79 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 95
TABLE 80 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 96
TABLE 81 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 96
TABLE 82 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 96
TABLE 83 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
TABLE 84 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
TABLE 85 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
TABLE 86 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 98
TABLE 87 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 98
TABLE 88 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 98
TABLE 89 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 99

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 19
FIGURE 2 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION 22
FIGURE 3 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS 23
FIGURE 4 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 24
FIGURE 5 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS 24
FIGURE 6 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING 25
FIGURE 7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 8 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID 28
FIGURE 9 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID 29
FIGURE 10 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 11 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 33
FIGURE 12 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 34
FIGURE 13 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031 34
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET 43
FIGURE 15 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023 52
FIGURE 16 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION) 53
FIGURE 17 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031) 53
FIGURE 18 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE 54
FIGURE 19 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023 59
FIGURE 20 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION) 60
FIGURE 21 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031) 60
FIGURE 22 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE 61
FIGURE 23 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023 66
FIGURE 24 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 67
FIGURE 25 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 67
FIGURE 26 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 68
FIGURE 27 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023) 73
FIGURE 28 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 100

APAC Age-Related Updated Macular Degeneration (AMD) Disease - ANTI VEGF Market - Industry Trends and Forecast to 2032